Revolution Medicines, Inc. (NASDAQ:RVMD) Receives $78.94 Average PT from Analysts

Revolution Medicines, Inc. (NASDAQ:RVMD) has been assigned a consensus rating of “Buy” from the eighteen ratings firms that are presently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, thirteen have assigned a buy recommendation and four have assigned a strong buy recommendation to the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $78.9412.

A number of research firms have weighed in on RVMD. Needham & Company LLC upped their target price on Revolution Medicines from $66.00 to $72.00 and gave the stock a “buy” rating in a report on Thursday, November 6th. Royal Bank Of Canada assumed coverage on Revolution Medicines in a research note on Monday, November 3rd. They issued an “outperform” rating and a $77.00 price target on the stock. JPMorgan Chase & Co. raised their price objective on Revolution Medicines from $71.00 to $82.00 and gave the company an “overweight” rating in a research report on Thursday, November 6th. HC Wainwright boosted their target price on shares of Revolution Medicines from $72.00 to $73.00 and gave the company a “buy” rating in a report on Thursday, November 6th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Revolution Medicines in a research note on Thursday, January 22nd.

Revolution Medicines Price Performance

Shares of NASDAQ RVMD opened at $97.33 on Friday. Revolution Medicines has a 1 year low of $29.17 and a 1 year high of $124.49. The stock has a market capitalization of $18.82 billion, a P/E ratio of -18.83 and a beta of 1.01. The company’s 50-day moving average is $94.13 and its 200 day moving average is $65.41. The company has a debt-to-equity ratio of 0.16, a current ratio of 8.05 and a quick ratio of 8.05.

Insider Buying and Selling at Revolution Medicines

In other news, COO Margaret A. Horn sold 75,000 shares of Revolution Medicines stock in a transaction that occurred on Wednesday, January 7th. The shares were sold at an average price of $100.56, for a total transaction of $7,542,000.00. Following the completion of the transaction, the chief operating officer directly owned 141,053 shares in the company, valued at approximately $14,184,289.68. This trade represents a 34.71% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Jack Anders sold 10,000 shares of the business’s stock in a transaction that occurred on Wednesday, January 7th. The stock was sold at an average price of $98.00, for a total value of $980,000.00. Following the completion of the sale, the chief financial officer directly owned 108,065 shares in the company, valued at approximately $10,590,370. This represents a 8.47% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 193,792 shares of company stock worth $16,647,040 over the last three months. Company insiders own 8.20% of the company’s stock.

Hedge Funds Weigh In On Revolution Medicines

Large investors have recently modified their holdings of the stock. Indiana Trust & Investment Management Co bought a new position in Revolution Medicines in the 4th quarter worth about $32,000. Global Retirement Partners LLC raised its holdings in Revolution Medicines by 1,002.8% in the fourth quarter. Global Retirement Partners LLC now owns 397 shares of the company’s stock worth $32,000 after buying an additional 361 shares during the last quarter. Torren Management LLC bought a new position in shares of Revolution Medicines in the fourth quarter worth approximately $33,000. CWM LLC grew its holdings in shares of Revolution Medicines by 171.3% during the second quarter. CWM LLC now owns 917 shares of the company’s stock valued at $34,000 after buying an additional 579 shares during the last quarter. Finally, GAMMA Investing LLC increased its position in shares of Revolution Medicines by 45.1% during the third quarter. GAMMA Investing LLC now owns 837 shares of the company’s stock valued at $39,000 after acquiring an additional 260 shares in the last quarter. Hedge funds and other institutional investors own 94.34% of the company’s stock.

About Revolution Medicines

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.